bioAffinity Technologies, Inc., based in San Antonio, TX, is a pioneering company focused on early-stage cancer diagnosis and targeted treatment. Their flagship product, CyPath Lung, utilizes advanced flow cytometry to accurately detect early-stage lung cancer, offering a non-invasive solution to address the critical need for early cancer detection.
Through innovative technology and rigorous research, bioAffinity Technologies is dedicated to revolutionizing cancer diagnosis at the cellular level. Their cutting-edge tests and therapies, such as CyPath Lung, aim to improve patient outcomes by enabling early detection of cancer, leading to increased survival rates and reduced medical costs.
Generated from the website
